Tests BMS-986463 in adults with advanced ovarian, uterine, or lung cancer
Tests a new drug, BMS-986463, at rising doses in adults with advanced cancers.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Key facts
- Where
- Barcelona, Madrid, and Pamplona, SpainSee the 3 sites
- Phase
- Phase 1
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Clinica Universidad de NavarraMadrid, SpainNot yet recruiting
- Clínica Universidad de navarraPamplona, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06476808EU 2025-523067-38-01
- Record updated
- 20 July 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.Read full original descriptionShow less
A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Inclusion: Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1; Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained; Participants must have an unresectable/metastatic carcinoma.
Exclusion: Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment; Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment; Participants must not have Leptomeningeal metastases; Other protocol-defined Inclusion/Exclusion criteria apply.